Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MB | P02144 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291294 | 1.00 | MAPT (0.47) | MAPTMEN1KMT2ANPC1MAPK1 | |
| SCHEMBL4291297 | 1.00 | MAPT (0.47) | MAPTMEN1KMT2ANPC1MAPK1 | |
| SCHEMBL4293600 | 0.87 | MAPT (0.46) | MAPTMEN1KMT2ANPC1MAPK1 | |
| SCHEMBL4293602 | 0.87 | MAPT (0.46) | MAPTMEN1KMT2ANPC1MAPK1 | |
| SCHEMBL13624918 | 0.87 | MAPT (0.46) | MAPTMEN1KMT2ANPC1MAPK1 | |
| SCHEMBL4296655 | 0.83 | PPARG (0.44) | MAPTMEN1KMT2ANPC1MAPK1 | |
| SCHEMBL4296650 | 0.83 | PPARG (0.44) | MAPTMEN1KMT2ANPC1MAPK1 | |
| SCHEMBL13624925 | 0.79 | NPC1 (0.48) | MAPTMEN1KMT2ANPC1MAPK1 | |
| SCHEMBL14476694 | 0.78 | HPGD (0.54) | MAPTMEN1KMT2ANPC1MAPK1 | |
| SCHEMBL7941711 | 0.77 | SMN1; SMN2 (0.64) | MAPTMEN1KMT2ANPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, KLK3, FOLH1 | MAPT 2473/4885MEN1 524/4885KMT2A 1702/4885 |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | MAPT 3032/4885MEN1 894/4885KMT2A 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.